Key result
Abciximab binds to αVβ3 and activated αMβ2 receptors in addition to the GPIIb/IIIa receptor, suggesting potential utility in other disorders where these receptors play a role.
Design
Review
Authors
Loading...
May support repurposing abciximab beyond GPIIb/IIIa inhibition; leaves open clinical translation in αVβ3/αMβ2-mediated disorders without prospective trials.
This review discusses the binding of abciximab to αVβ3 and αMβ2 receptors and its potential implications in preventing or treating disorders involving these receptors.
Barry S. Coller (1999) conducted a review in Platelet-mediated ischemic cardiovascular disease. Abciximab was evaluated. Abciximab binds to αVβ3 and activated αMβ2 receptors in addition to the GPIIb/IIIa receptor, suggesting potential utility in other disorders where these receptors play a role.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: